Vor Bio says telitacicept Phase 3 analysis shows 42% minimal symptom expression in gMG through 48 weeks

By Public Technologies
  • Vor Bio released a new post hoc analysis from a China Phase 3 trial of telitacicept in generalized myasthenia gravis.
  • Results were presented in an oral session at the MGFA Scientific Session during the 2026 AANEM Annual Meeting.
  • Patients showed broad, sustained symptom relief through 48 weeks, with more participants reaching very low symptom burden over time.
  • Benefits appeared durable once achieved, supporting continued treatment use across a range of starting disease severity.
  • Safety remained consistent with earlier reports, with no new issues flagged over the longer follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290805PRIMZONEFULLFEED9835380) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.